Herbert Treutlein

Dr. Herbert Treutlein

orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1992 in Biochemistry
Verified
Journal Article
Closed access
MLMark A. Lemmon
Mark A. Lemmon
JFJohn M. Flanagan
John M. Flanagan
HTHerbert Treutlein
Herbert Treutlein
JZJian Zhang
Jian Zhang
DEDonald M. Engelman
Donald M. Engelman

1 March 1994 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
MLMark A. Lemmon
Mark A. Lemmon
HTHerbert Treutlein
Herbert Treutlein
PAPaul D. Adams
Paul D. Adams
ABAxel T. Brünger
Axel T. Brünger
DEDonald M. Engelman
Donald M. Engelman

1 January 2006 in Blood
Verified
Journal Article
Closed access
PDF file
ILIsabelle S. Lucet
Isabelle S. Lucet
EFEmmanuelle Fantino
Emmanuelle Fantino
MSMichelle Styles
Michelle Styles
RBRebecca Bamert
Rebecca Bamert
OPOnisha Patel
Onisha Patel
JRJamie Rossjohn
Jamie Rossjohn
JAK2, a member of the Janus kinase (JAK) family of protein tyrosine kinases (PTKs), is an important intracellular mediator of cytokine signaling. Mutations of the JAK2 gene are associated with hematologic cancers, and aberrant JAK activity is also associated with a number of immune diseases, including rheumatoid arthritis. Accordingly, the development of JAK2-specific inhibitors has tremendous clinical relevance. Critical to the function of JAK2 is its PTK domain. We report the 2.0 Å crystal structure of the active conformation of the JAK2 PTK domain in complex with a high-affinity, pan-JAK inhibitor that appears to bind via an induced fit mechanism. This inhibitor, the tetracyclic pyridone 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-1, was buried deep within a constricted ATP-binding site, in which extensive interactions, including residues that are unique to JAK2 and the JAK family, are made with the inhibitor. We present a structural basis of high-affinity JAK-specific inhibition that will undoubtedly provide an invaluable tool for the further design of novel, potent, and specific therapeutics against the JAK family.

13 August 2013 in Cancer Research
Verified
Journal Article
Open access
PDF file
JSJustine R. Stehn
Justine R. Stehn
NHNikolas Haass
Nikolas Haass
TBTeresa Bonello
Teresa Bonello
MDMelissa Desouza
Melissa Desouza
GKGregg Kottyan
Gregg Kottyan
PGPeter Gunning
Peter Gunning
The actin cytoskeleton is a potentially vulnerable property of cancer cells, yet chemotherapeutic targeting attempts have been hampered by unacceptable toxicity. In this study, we have shown that it is possible to disrupt specific actin filament populations by targeting isoforms of tropomyosin, a core component of actin filaments, that are selectively upregulated in cancers. A novel class of anti-tropomyosin compounds has been developed that preferentially disrupts the actin cytoskeleton of tumor cells, impairing both tumor cell motility and viability. Our lead compound, TR100, is effective in vitro and in vivo in reducing tumor cell growth in neuroblastoma and melanoma models. Importantly, TR100 shows no adverse impact on cardiac structure and function, which is the major side effect of current anti-actin drugs. This proof-of-principle study shows that it is possible to target specific actin filament populations fundamental to tumor cell viability based on their tropomyosin isoform composition. This improvement in specificity provides a pathway to the development of a novel class of anti-actin compounds for the potential treatment of a wide variety of cancers. Cancer Res; 73(16); 5169–82. ©2013 AACR.

1 December 1992 in Biochemistry
Verified
Journal Article
Closed access
HTHerbert Treutlein
Herbert Treutlein
MLMark A. Lemmon
Mark A. Lemmon
DEDonald M. Engelman
Donald M. Engelman
ABAxel Brunger
Axel Brunger

4 November 2005 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
ABAkin Budi
Akin Budi
FLF. Sue Legge
F. Sue Legge
HTHerbert Treutlein
Herbert Treutlein
IYIrene Yarovsky
Irene Yarovsky